Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1016/j.ijid.2020.09.1447 http://scihub22266oqcxt.onion/10.1016/j.ijid.2020.09.1447 33002613!7521212!33002613     free     free     free Deprecated: Implicit conversion from float 213.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 213.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 213.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 213.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Int+J+Infect+Dis 2020 ; 101 (ä): 59-64 Nephropedia Template TP {{tp|p=33002613|t=2020. Tocilizumab therapy for COVID-19: A comparison of subcutaneous and intravenous therapies |pdf=|usr=}}{{33002613}} gab.com Text Tocilizumab therapy for COVID-19: A comparison of subcutaneous and intravenous therapies JO: Int J Infect Dis http://www.kidney.de/pget.php?&tw=1&pmid=33002613 #FOAvip BACKGROUND: The release of pro-inflammatory cytokines, resulting in cytokine storm syndrome, contributes to the morbidity and mortality associated with COVID-19 disease. This study aimed to compare the effects of intravenous (IV) and subcutaneous (SC) tocilizumab, an IL-6 receptor antagonist, on respiratory parameters and clinical outcome in patients with COVID 19. METHODS: We performed a retrospective cohort study of hospitalized patients with COVID-19 treated with either IV or SC tocilizumab from March 26, 2020, to May 18, 2020. Respiratory parameters seven days after receiving tocilizumab therapy were compared to baseline measurements. All patients were assessed until discharged from the hospital. RESULTS: Tocilizumab was administered to 125 patients: 65 received IV, and 60 received SC therapy. At day seven, 52% of the IV group patients demonstrated improvement in respiratory parameters, compared to 28% in the SC group (P = 0.01). Mortality rates at days seven and 28 were 15% and 37%, respectively, in the IV group and 17% and 50%, respectively, in the SC group (PNS). The in-hospital mortality rate was 38% for the IV group versus 57% for the SC group (P = 0.04). More than 90% of patients in each group received corticosteroids; however, significantly more patients received convalescent plasma in the IV group. CONCLUSIONS: At the doses used in this study, IV tocilizumab is preferred over SC therapy to treat cytokine storm syndrome due to COVID-19. Twit Text FOAVip Tocilizumab therapy for COVID-19: A comparison of subcutaneous and intravenous therapies ????Int J Infect Dis http://www.kidney.de/pget.php?&tw=1&pmid=33002613 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=33002613 #FOAvip English Wikipedia <ref>{{Cite pmid|33002613}}</ref> Tocilizumab therapy for COVID-19: A comparison of subcutaneous and intravenous therapies #MMPMID33002613 Kaminski MA; Sunny S; Balabayova K; Kaur A; Gupta A; Abdallah M; Quale J Int J Infect Dis 2020[Dec]; 101 (ä): 59-64 PMID33002613show ga BACKGROUND: The release of pro-inflammatory cytokines, resulting in cytokine storm syndrome, contributes to the morbidity and mortality associated with COVID-19 disease. This study aimed to compare the effects of intravenous (IV) and subcutaneous (SC) tocilizumab, an IL-6 receptor antagonist, on respiratory parameters and clinical outcome in patients with COVID 19. METHODS: We performed a retrospective cohort study of hospitalized patients with COVID-19 treated with either IV or SC tocilizumab from March 26, 2020, to May 18, 2020. Respiratory parameters seven days after receiving tocilizumab therapy were compared to baseline measurements. All patients were assessed until discharged from the hospital. RESULTS: Tocilizumab was administered to 125 patients: 65 received IV, and 60 received SC therapy. At day seven, 52% of the IV group patients demonstrated improvement in respiratory parameters, compared to 28% in the SC group (P = 0.01). Mortality rates at days seven and 28 were 15% and 37%, respectively, in the IV group and 17% and 50%, respectively, in the SC group (PNS). The in-hospital mortality rate was 38% for the IV group versus 57% for the SC group (P = 0.04). More than 90% of patients in each group received corticosteroids; however, significantly more patients received convalescent plasma in the IV group. CONCLUSIONS: At the doses used in this study, IV tocilizumab is preferred over SC therapy to treat cytokine storm syndrome due to COVID-19. |*COVID-19 Drug Treatment[MESH] |*SARS-CoV-2[MESH] |Administration, Intravenous[MESH] |Adult[MESH] |Aged[MESH] |Antibodies, Monoclonal, Humanized/*administration & dosage[MESH] |COVID-19/mortality[MESH] |Cytokine Release Syndrome/drug therapy[MESH] |Female[MESH] |Hospital Mortality[MESH] |Humans[MESH] |Injections, Subcutaneous[MESH] |Male[MESH] |Middle Aged[MESH]Tocilizumab therapy for COVID-19: A comparison of subcutaneous and int(epmc).pdf DeepDyve Pubget Overpricing